Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

728
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
728
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

622
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
622
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

215
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
215
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

208
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Related Experiment Video

Updated: Aug 8, 2025

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.9K

Inclisiran: A Review in Hypercholesterolemia.

James E Frampton1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|March 4, 2023
PubMed
Summary
This summary is machine-generated.

Inclisiran, a novel siRNA therapy, significantly reduces low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 synthesis. Its infrequent dosing offers a convenient option for managing hypercholesterolemia, especially for statin-intolerant patients.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Related Experiment Videos

Last Updated: Aug 8, 2025

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • RNA Interference Therapeutics

Background:

  • Hypercholesterolemia poses a significant risk for atherosclerotic cardiovascular disease (ASCVD).
  • Current lipid-lowering therapies (LLTs) like statins have limitations in efficacy and tolerability for some patients.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating LDL cholesterol levels.

Purpose of the Study:

  • To evaluate the efficacy and safety of inclisiran, a small interfering RNA (siRNA) targeting PCSK9 synthesis, in managing hypercholesterolemia.
  • To assess inclisiran's role as an adjunct to diet and/or other LLTs, including in patients with statin intolerance.

Main Methods:

  • Inclisiran is a subcutaneously administered siRNA that inhibits hepatic PCSK9 synthesis.
  • Clinical trials involved administration at day 1, day 90, and then every six months.
  • Evaluated LDL-C reduction in patients with hypercholesterolemia, with or without existing statin therapy.

Main Results:

  • Twice-yearly inclisiran injections approximately halved LDL-C levels in patients with hypercholesterolemia.
  • Efficacy was observed irrespective of concomitant statin use.
  • Inclisiran demonstrated a safety and tolerability profile similar to placebo, with transient injection-site reactions being more common.

Conclusions:

  • Inclisiran represents a valuable new antihyperlipidemic agent, offering an alternative or adjunct to statin therapy.
  • Its infrequent dosing regimen provides a significant convenience advantage over other non-statin LLTs.
  • Further confirmation of cardiovascular event reduction is pending, but inclisiran shows promise in managing hypercholesterolemia.